Search Results - "Sarosiek, T."

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy by Aapro, M., Rugo, H., Rossi, G., Rizzi, G., Borroni, M.E., Bondarenko, I., Sarosiek, T., Oprean, C., Cardona-Huerta, S., Lorusso, V., Karthaus, M., Schwartzberg, L., Grunberg, S.

“…Antiemetic guidelines recommend co-administration of agents that target multiple molecular pathways involved in emesis to maximize prevention and control of…”
Get full text

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results by Pivot, X., Bondarenko, I., Nowecki, Z., Dvorkin, M., Trishkina, E., Ahn, J.-H., Im, S.-A., Sarosiek, T., Chatterjee, S., Wojtukiewicz, M.Z., Shparyk, Y., Moiseyenko, V., Bello, M., Semiglazov, V., Lee, Y., Lim, J.

“…The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete…”
Get full text

A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC) by Krivorotko, P., Karaszewska, B., Chan, S., Wieczorek-Rutkowska, M., Sarosiek, T., Shomova, M.V., Ovchinnikova, E., Zarate, J.P., Babanrao Pisal, C., Smith, L., Manikhas, A.

Get full text

Biochemical indices for the assessment of nutritional status during hematopoietic stem cell transplantation: are they worth using? A single center experience by RZEPECKI, P, BARZAL, J, SAROSIEK, T, SZCZYLIK, C

“…Hematopoietic stem cell transplantation (HSCT) is being used increasingly in an attempt to cure many hematological disorders, solid tumors and autoimmune…”
Get full text

Which Parameters of Nutritional Status Should We Choose for Nutritional Assessment During Hematopoietic Stem Cell Transplantation? by Rzepecki, P, Barzal, J, Sarosiek, T, Oborska, S, Szczylik, C

“…Abstract Since changes in nutritional indices after hematopoietic stem cell transplantation (HSCT) have not been well studied, there is no definition of risk…”
Get full text

Antisense therapy in cancer by Pawlak, W., Zolnierek, J., Sarosiek, T., Szczylik, C.

“…This review discusser laboratory and clinical studies of antisense oligodeoxynucleotides as potential treatments for haematological malignancies and solid…”
Get full text

Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience by Rzepecki, P, Sarosiek, T, Barzal, J, Oborska, S, Nurzynski, P, Wasko, A, Szczylik, C

“…Oral mucositis (OM) is one of the most debilitating and common side effects in patients treated with high-dose chemotherapy supported by haematopoietic stem…”
Get more information

Prevention of Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation with Valganciclovir: Single Center Experience by Rzepecki, P., Barzal, J., Sarosiek, T., Oborska, S., Szczylik, C.

Get full text

How can we help patients with refractory chronic graft versus host disease- single centre experience by Rzepecki, P, Barzal, J, Sarosiek, T, Oborska, S, Szczylik, C

“…Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and mortality in long-term survivors of allogeneic haematopoietic stem cell…”
Get more information

Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience by Rzepecki, P, Zolnierek, J, Sarosiek, T, Langiewicz, P, Szczylik, C

“…We evaluated the efficacy of allogeneic non-myeloablative stem cell transplantation (NST) in patients with metastatic renal cell carcinoma (RCC). A total of 5…”
Get more information

Nutritional assessment during allogeneic hematopoietic stem cell transplantation: single centre experience by Rzepecki, R, Barzal, J, Sarosiek, T, Oborska, S, Szczylik, C

“…The aim of this study was to analyse the changes in several parameters of nutritional status, acute phase proteins' levels and evaluation of the usefulness of…”
Get more information

Multimodality treatment of germ cell cancer patients who had progression or relapse after high dose chemotherapy and autologous bone marrow transplantation by Sarosiek, T, Rzepecki, P, Langiewicz, P, Zolnierek, J, Barzal, J, Szczylik, C

“…When a patient with germ cell tumor (GCT) fails to be cured with high dose chemotherapy (HDC) and autologous haematopoietic stem cell transplantation (auto-…”
Get more information

P156 - 3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting by Pivot, X., Bondarenko, I., Dvorkin, M., Sarosiek, T., Wojtukiewicz, M., Shparyk, Y., Kim, Y., Lim, J.

Get full text

3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting by Pivot, X., Bondarenko, I., Dvorkin, M., Sarosiek, T., Wojtukiewicz, M., Shparyk, Y., Kim, Y., Lim, J.

Get full text

319PA randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC) by Krivorotko, P, Karaszewska, B, Chan, S, Wieczorek-Rutkowska, M, Sarosiek, T, Shomova, M V, Ovchinnikova, E, Zarate, J P, Babanrao Pisal, C, Smith, L, Manikhas, A

Get full text

O-027A pivotal phase 3 trial of MABp1 in advanced colorectal cancer by Hickish, T, Andre, T, Wyrwicz, L, Saunders, M, Sarosiek, T, Nemecek, R, Kocsis, J, Stecher, M, de Gramont, A

Get full text

O-027 A pivotal phase 3 trial of MABp1 in advanced colorectal cancer by Hickish, T., André, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Nemecek, R., Kocsis, J., Stecher, M., de Gramont, A.

Get full text

A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB by Ajani, J.A., Udrea, A., Sarosiek, T., Shenker, M., Morgan, C., Pikiel, J., Wojcik, E., Swinson, D., Joseph, M., Luft, A., Salek, T., Tournigand, C., Ferry, D., Zhang, Y., Long, A., Kuo, W-L., Gao, L., Kauh, J., Mansoor, W.

Get full text

One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment by Pivot, X., Bondarenko, I.M., Nowecki, Z., Dvorkin, M., Trishkina, E., Ahn, J.H., Vinnyk, Y., Im, S-A., Sarosiek, T., Chatterjee, S., Wojtukiewicz, M., Moiseyenko, V., Shparyk, Y., Bello III, M., Semiglazov, V., Younju, L., Lim, J.

Get full text

Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) by Stenzl, A., Feyerabend, S., Syndikus, I., Sarosiek, T., Kübler, H., Heidenreich, A., Cathomas, R., Grüllich, C., Loriot, Y., Perez Gracia, S.L., Gillessen, S., Klinkhardt, U., Schröder, A., Schönborn-Kellenberger, O., Reus, V., Koch, S.D., Hong, H.S., Seibel, T., Fizazi, K., Gnad-Vogt, U.

Get full text